Structural basis for ineffective T-cell responses to MHC anchor residue-improved “heteroclitic” peptides

MHC anchor residue-modified “heteroclitic” peptides have been used in many cancer vaccine trials and often induce greater immune responses than the wild-type peptide. The best-studied system to date is the decamer MART-1/Melan-A(26–35) peptide, EAAGIGILTV, where the natural alanine at position 2 has...

Descripción completa

Detalles Bibliográficos
Autores principales: Madura, Florian, Rizkallah, Pierre J, Holland, Christopher J, Fuller, Anna, Bulek, Anna, Godkin, Andrew J, Schauenburg, Andrea J, Cole, David K, Sewell, Andrew K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Molecular Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357396/
https://www.ncbi.nlm.nih.gov/pubmed/25471691
http://dx.doi.org/10.1002/eji.201445114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4357396/
https://www.ncbi.nlm.nih.gov/pubmed/25471691
http://dx.doi.org/10.1002/eji.201445114

Ejemplares similares